PubMed Sikiric, P., Seiwerth, S., Rucman, R., Kolenc, D., Vuletic, L.B., Drmic, D., Grgic, T., Strbe, S., Zukanovic, G., Crvenkovic, D., Madzarac, G., Rukavina, I., Sucic, M., Baric, M., Staroveski, M., Zoric, Z., Turkalj, I., & Aralica, G
Oral vs Injectable BPC 157 BPC 157 is also sold or discussed in oral forms, including capsules and tablets
Cycle length: Common research protocols range from 1224 weeks for weight and metabolic outcomes
Oral therapy is generally unsuitable for pernicious anaemia or conditions affecting the terminal ileum (where B12 is absorbed), as these patients lack intrinsic factor or have damaged absorption sites
Extended, Controlled Release for Consistency: Utilizing iontophoresis technology, Push Patch NAD+ 1300mg offers a stable, continuous release of NAD+ over the entire wear period, ensuring consistent therapeutic levels without the variability seen with oral or injectable NAD+ delivery methods